Northrop Grumman (NYSE:NOC) Stock Declines Amidst Strong Q1 Earnings and Lowered EPS Guidance

  • Despite strong first-quarter results, Northrop Grumman (NYSE:NOC) stock is currently falling due to a lower-than-expected full-year EPS forecast.
  • A UBS analyst set a new price target of $745, implying a 26.35% potential upside, leading some to view the recent 16% stock decline as a "Strong Buy" opportunity.
  • The company's Q1 earnings per share of $6.14 and sales of $9.88 billion both surpassed analyst estimates, but the 2026 adjusted EPS guidance of between $27.40 and $27.90 fell short of the $28.01 consensus.

Northrop Grumman (NYSE:NOC) is a global aerospace and defense technology company. It operates in various sectors, including aeronautics, defense systems, and space systems, providing advanced solutions to government and commercial customers. On April 23, 2026, a UBS analyst set a new price target on Northrop Grumman at $745, implying a 26.35% potential upside from its price of $589.65 at the time.

Despite this optimistic target, the company's stock price is currently falling. As highlighted by Benzinga, shares are sinking after Northrop Grumman reported its first-quarter earnings. This recent drop follows a 16% stock decline, which has led some to consider the stock a "Strong Buy," as noted by Seeking Alpha, because it is trading below its perceived value.

The company's first-quarter results were strong, beating analyst expectations. Northrop Grumman reported quarterly earnings of $6.14 per share, which was higher than the consensus estimate of $6.09. The company also posted quarterly sales of $9.88 billion, surpassing the analyst estimate of $9.75 billion and showing a 4.36 percent increase from the same quarter a year ago.

The negative market reaction is tied to the company's forecast for the full year. Northrop Grumman affirmed its 2026 adjusted earnings per share (EPS) guidance to be between $27.40 and $27.90. EPS represents the company's profit per share, and this forecast is below the analyst consensus estimate of $28.01, causing concern among investors.

While the company's sales outlook of $43.50 billion to $44 billion is in line with estimates, the lower earnings guidance suggests a "ramp-up year" with muted margin growth. This short-term outlook contrasts with the view that the stock's recent decline presents a valuable buying opportunity, aligning with the significant upside suggested by the UBS price target.

About the Author
Andrew Wynn

Market news and analyst rating coverage

Andrew Wynn writes market news and analyst-rating coverage for the FMP blog, tracking price-target revisions, broker upgrades and downgrades, and earnings developments across U.S. equities. His posts distill fast-moving market events into clear, factual summaries grounded in financial data.

Related

Financial data for every need

Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.

Create Free Account